Teva reports positive results in study for prevention of chronic and episodic migraine Major advance in the development of new treatment options for millions of patients
“Copaxone and Azilect came from Israeli universities. Why wouldn’t we tap into this incredible expertise and innovation of Israeli Universities to find the next jewels.”
“Today we can understand the processes resultingin disease and response to drugs in individual patients with greater precision than ever before.”
"Our collaboration with Teva will contribute greatly to the Korean pharmaceutical industry by supplying innovative medicines at affordable prices."
“Our DNA is the combination of P&G and Teva. Our mission is to understand what people wantand need, and then find innovative ways to deliver that.”
“We are excited to develop environmentally friendly technologies to create a healthier world for our customers worldwide.“
All News › Top News Jul 20, 2017 NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma Learn More Share Top News Jul 13, 2017 Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders Learn More Share Top News Jul 11, 2017 Teva to Report Second Quarter 2017 Financial Results on August 3, 2017 Learn More Share Top News Jul 11, 2017 Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology Learn More Share Top News Jun 29, 2017 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab) Learn More Share
Top News Jul 20, 2017 NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma Learn More
Top News Jul 13, 2017 Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders Learn More
Top News Jul 11, 2017 Teva to Report Second Quarter 2017 Financial Results on August 3, 2017 Learn More
Top News Jul 11, 2017 Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology Learn More
Top News Jun 29, 2017 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab) Learn More
TAPI Launches Upgraded Customer Portal! TAPI has launched its upgraded customer portal, TAPI Online. This exciting new portal provides full support for API projects, including a range of tools and a comprehensive API document library. Discover more
TAPI has launched its upgraded customer portal, TAPI Online. This exciting new portal provides full support for API projects, including a range of tools and a comprehensive API document library.
Teva’s Healthcare Heroes Teva’s Healthcare Heroes Awards program honors the memory of Richard Egosi, former Teva group EVP and chief legal officer Discover more
Teva’s Healthcare Heroes Awards program honors the memory of Richard Egosi, former Teva group EVP and chief legal officer
How Our Uniqueness Creates Healthcare Confidence Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it:
Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it: